1. Home
  2. CEV vs MAIA Comparison

CEV vs MAIA Comparison

Compare CEV & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance California Municipal Income Trust Shares of Beneficial Interest

CEV

Eaton Vance California Municipal Income Trust Shares of Beneficial Interest

N/A

Current Price

$10.11

Market Cap

75.4M

Sector

Finance

ML Signal

N/A

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

N/A

Current Price

$1.20

Market Cap

79.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CEV
MAIA
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.4M
79.0M
IPO Year
1998
2022

Fundamental Metrics

Financial Performance
Metric
CEV
MAIA
Price
$10.11
$1.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $12.00
AVG Volume (30 Days)
38.8K
★ 675.5K
Earning Date
01-01-0001
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 33.33
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.77
$0.87
52 Week High
$10.84
$3.19

Technical Indicators

Market Signals
Indicator
CEV
MAIA
Relative Strength Index (RSI) 49.14 42.47
Support Level $9.97 N/A
Resistance Level $10.47 $1.48
Average True Range (ATR) 0.22 0.07
MACD 0.03 -0.01
Stochastic Oscillator 65.75 28.00

Price Performance

Historical Comparison
CEV
MAIA

About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest

Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: